Nikon NIKKOR Z DX 50-250mm f/4.5-6.3 VR Mirrorless Camera Lens () JMA707DA

Product Information

Fluticasone propionate given by inhalation at recommended doses has a glucocorticoid anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma, with less adverse effects than when corticosteroids are administered systemically. The trials had a 4 week run-in period during which all subjects received openlabel salmeterol/ FP 50/250 to standardize COPD pharmacotherapy and With a 7-bladed rounded diaphragm I can't get much in the way of sunstars. The best I can get is is some soft stars at the smallest aperture.

As you can see at Sample Images, this is a fantastic lens optically, and it's tiny, works well and fast and is inexpensive. This is one of Nikon's Best Lenses. This percentage can be represented on a pie chart for visualization. Let us suppose that the whole pie chart represents the 250 value. Now, we find 50 percent of 250, which is 125. The area occupied by the 125 value will represent the 50 percent of the total 250 value. The remaining region of the pie chart will represent 50 percent of the total 250 value. The 100% of 250 will cover the whole pie chart as 250 is the total value. The image from this lens does not change size as focused, which is excellent — but I have no idea how you'd follow focus with this lens. Weighing in at just 405g / 14.3oz, the plastic bodied Nikon Z DX 50-250mm F4.5-6.3 VR is very light for a super-telephoto zoom lens. The 50 percent of 250 is equal to 125. It can be easily calculated by dividing 50 by 100 and multiplying the answer with 250 to get 125.The benefits of inhaled fluticasone propionate therapy should minimise the need for oral steroids, but patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. Therefore these patients should be treated with special care and adrenocortical function regularly monitored. Patients who have required high dose emergency corticosteroid therapy in the past may also be at risk. This possibility of residual impairment should always be borne in mind in emergency and elective situations likely to produce stress, and appropriate corticosteroid treatment must be considered. The extent of the adrenal impairment may require specialist advice before elective procedures. Well controlled asthma; less than or equal to 2 days with symptom score greater than 1 (symptom score 1 defined as 'symptoms for one short period during the day'), SABA use on less than or equal to 2 days and less than or equal to 4 occasions/week, greater than or equal to 80% predicted morning peak expiratory flow, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy Chromatic aberrations, typically seen as blue or purple fringes along contrasty edges, were not really apparent in our test shots, only appearing in very high contrast areas. Vignetting The Nikkor Z 28mm has a minimum focusing distance of 50cm / 1.64ft with a maximum magnification of 0.23x.

Placebo-controlled clinical trials, over 6 and 12 months, have shown that regular use of Seretide 50/500 micrograms improves lung function and reduces breathlessness and the use of relief medication. A clear benefit has not been shown as compared to inhaled fluticasone propionate alone used as initial maintenance therapy when one or two of the criteria of severity are missing. In general inhaled corticosteroids remain the first line treatment for most patients. Seretide is not intended for the initial management of mild asthma. Seretide 50 microgram/100 micrograms strength is not appropriate in adults and children with severe asthma; it is recommended to establish the appropriate dosage of inhaled corticosteroid before any fixed-combination can be used in patients with severe asthma. If you look carefully at the lens roadmap image, you will see that one of the two new lenses is a bit longer than the other. It looks like one is 50-200mm and the other is 50-250mm or so. This is also shown more clearly on the older lens roadmap displayed here in this dpreview article:

In a 12 week trial of children 4 to 11 years of age [n=203] randomized in a parallel-group study with persistent asthma and who were symptomatic on inhaled corticosteroid, safety was the primary objective. Children received either salmeterol/fluticasone propionate (50/100 micrograms) or fluticasone propionate (100 micrograms) alone twice daily. Two children on salmeterol/fluticasone propionate and 5 children on fluticasone propionate withdrew because of worsening asthma. After 12 weeks no children in either treatment arm had abnormally low 24 hour urinary cortisol excretion. There were no other differences in safety profile between the treatment arms. It features a rounded 7-blade diaphragm which creates an attractive blur to out-of-focus areas of the image and an internal focusing mechanism which means the lens barrel doesn't move.

Co-administration of ketoconazole (400 mg orally once daily) and salmeterol (50 micrograms inhaled twice daily) in 15 healthy subjects for 7 days resulted in a significant increase in plasma salmeterol exposure (1.4-fold Cmax and 15-fold AUC). This may lead to an increase in the incidence of other systemic effects of salmeterol treatment (e.g. prolongation of QTc interval and palpitations) compared with salmeterol or ketoconazole treatment alone (see section 4.4). The dose should be titrated to the lowest dose at which effective control of symptoms is maintained. Where the control of symptoms is maintained with the lowest strength of the combination given twice daily then the next step could include a test of inhaled corticosteroid alone. Cushing's syndrome, Cushingoid features, Adrenal suppression, Growth retardation in children and adolescents, Decreased bone mineral density There is no need to adjust the dose in elderly patients or in those with renal impairment. There are no data available for use of Seretide in patients with hepatic impairment.

Lens Handling and Build Quality

In trial SAM101667, in 158 children aged 6 to 16 years with symptomatic asthma, the combination of salmeterol/fluticasone propionate is equally efficacious to doubling the dose of fluticasone propionate regarding symptom control and lung function. This study was not designed to investigate the effect on exacerbations. This 50-250mm lens is absolutely brilliant. It's small, light weight, collapses for carrying, focusses super-close, has great image stabilization (VR), and is optically essentially flawless. As with other inhalation therapy paradoxical bronchospasm may occur with an immediate increase in wheezing and shortness of breath after dosing. Paradoxical bronchospasm responds to a rapid-acting bronchodilator and should be treated straightaway. Seretide Accuhaler should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.

Concomitant use of systemic ketoconazole significantly increases systemic exposure to salmeterol. This may lead to an increase in the incidence of systemic effects (e.g. prolongation in the QTc interval and palpitations). Concomitant treatment with ketoconazole or other potent CYP3A4 inhibitors should therefore be avoided unless the benefits outweigh the potentially increased risk of systemic side effects of salmeterol treatment (see section 4.5). An increase in the incidence of pneumonia, including pneumonia requiring hospitalisation, has been observed in patients with COPD receiving inhaled corticosteroids. There is some evidence of an increased risk of pneumonia with increasing steroid dose but this has not been demonstrated conclusively across all studies.

Autofocus Performance

This lens only ships with front and rear lens caps - there is no lens hood or any kind of case included in the box. Focal Range This lens uses a stepping motor for fast, quiet and precise auto-focusing and full-time manual focus override is also possible. Two multi-centre 26-week studies were conducted to compare the safety and efficacy of salmeterol-FP versus FP alone, one in adult and adolescent subjects (AUSTRI trial), and the other in paediatric subjects 4-11 years of age (VESTRI trial). For both studies, enrolled subjects had moderate to severe persistent asthma with history of asthma-related hospitalisation or asthma exacerbation in the previous year. The primary objective of each study was to determine whether the addition of LABA to ICS therapy (salmeterol-FP) was non-inferior to ICS (FP) alone in terms of the risk of serious asthma related events (asthma-related hospitalisation, endotracheal intubation, and death). A secondary efficacy objective of these studies was to evaluate whether ICS/LABA (salmeterol-FP) was superior to ICS therapy alone (FP) in terms of severe asthma exacerbation (defined as deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or an in-patient hospitalisation or emergency department visit due to asthma that required systemic corticosteroids).